PNEUMOCOCCAL VACCINATION WITH 13-VALENT POLYSACCHARIDE CONJUGATE VACCINE FOR OLDER ADULTS WITH CHRONIC CONDITIONS: BUDGET IMPACT ANALYSIS IN COLOMBIA

被引：0
|
作者：
LaRotta, J. [1 ]
Sanchez, Reyes J. M. [2 ]
Gamboa, Castano N. [1 ]
机构：
[1] Pfizer SAS, Bogota, Colombia
[2] Pfizer SAS, Bogota, Cun, Colombia
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC103
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [41] An Open-label Trial to Assess the Safety of 13-Valent Pneumococcal Conjugate Vaccine in Older Adults, Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine.
    Schwarz, T. F.
    Pauksens, K.
    Juergens, C.
    Jayawardene, D.
    Emini, E. A.
    Gruber, W. C.
    Scott, D. A.
    Schmoele-Thoma, B.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 : S30 - S30
  • [42] Impact of 13-valent pneumococcal conjugate vaccine on otitis media bacteriology
    Zhao, Alice S.
    Boyle, Sean
    Butrymowicz, Anna
    Engle, Robert D.
    Roberts, Jason M.
    Mouzakes, Jason
    INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2014, 78 (03) : 499 - 503
  • [43] Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults
    Gladstone, Rebecca A.
    Jefferies, Johanna M.
    Faust, Saul N.
    Clarke, Stuart C.
    EXPERT REVIEW OF VACCINES, 2012, 11 (08) : 889 - 902
  • [44] The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly
    van Werkhoven, Cornelis H.
    Huijts, Susanne M.
    Bolkenbaas, Marieke
    Grobbee, Diederick E.
    Bonten, Marc J. M.
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (12) : 1835 - 1838
  • [45] Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
    Schmoele-Thoma, Beate
    van Cleeff, Martin
    Greenberg, Richard N.
    Gurtman, Alejandra
    Jones, Thomas R.
    Sundaraiyer, Vani
    Gruber, William C.
    Scott, Daniel A.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 575 - 583
  • [46] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Peterson, James T.
    Stacey, Helen L.
    MacNair, John E.
    Li, Jianing
    Hartzel, Jonathan S.
    Sterling, Tina M.
    Benner, Patrice
    Tamms, Gretchen M.
    Musey, Luwy K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 540 - 548
  • [47] Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality
    Harboe, Zitta Barrella
    Dalby, Tine
    Weinberger, Daniel M.
    Benfield, Thomas
    Molbak, Kare
    Slotved, Hans Christian
    Suppli, Camilla H.
    Konradsen, Helle Bossen
    Valentiner-Branth, Palle
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (08) : 1066 - 1073
  • [48] MODELLING BUDGET IMPACT (BI) OF VACCINATING AT-RISK ADULTS AND THE ELDERLY WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN GERMANY
    Jiang, Y.
    Gauthier, A.
    Annemans, L.
    van der Linden, M.
    Nicolas-Spony, L.
    Bresse, X.
    VALUE IN HEALTH, 2011, 14 (07) : A268 - A268
  • [49] Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
    Esposito, Susanna
    Principi, Nicola
    JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
  • [50] Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine
    Bryant, Kristina A.
    Block, Stan L.
    Baker, Sherryl A.
    Gruber, William C.
    Scott, Daniel A.
    PEDIATRICS, 2010, 125 (05) : 866 - 875
12345